LATS1 and neoplasm: It is well known that the level of tumor immunogenicity affects the survival of tumor cells, and it has been found that inhibition of LATS1/2 kinase in the Hippo pathway seems to enhance tumor immunogenicity and thus can achieve the purpose of LC treatment (174).